Evaluation of Hyponatremia in Infants on Vasopressin Therapy.

ABSTRACT:

Objective

Vasopressin has systemic vasoconstrictive yet pulmonary vasodilatory effects, making it an ideal agent for hypotension management in infants with congenital diaphragmatic hernia (CDH)-associated pulmonary hypertension. The side effects of vasopressin in this population, such as hyponatremia, are understudied. This study aims to characterize the effect of vasopressin on sodium concentrations in infants with and without CDH.

Methods

This was a retrospective review of patients who received vasopressin while admitted to a level IV neonatal intensive care unit. The primary outcome was the incidence of hyponatremia (blood sodium <135 mmol/L) during vasopressin therapy. Secondary outcomes included time to hyponatremia, dose and duration of vasopressin, incidence of severe

SUBMITTER: Hawkins C 

PROVIDER: S-EPMC11321805 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature